MCID: EXC002
MIFTS: 41

Exocrine Pancreatic Insufficiency

Categories: Endocrine diseases

Aliases & Classifications for Exocrine Pancreatic Insufficiency

MalaCards integrated aliases for Exocrine Pancreatic Insufficiency:

Name: Exocrine Pancreatic Insufficiency 12 54 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13316
MeSH 43 D010188
NCIt 49 C84316
SNOMED-CT 67 47367009
ICD10 32 K86.81
UMLS 71 C0267963

Summaries for Exocrine Pancreatic Insufficiency

MalaCards based summary : Exocrine Pancreatic Insufficiency is related to shwachman-diamond syndrome 1 and pancreatic agenesis 1. An important gene associated with Exocrine Pancreatic Insufficiency is COX4I2 (Cytochrome C Oxidase Subunit 4I2), and among its related pathways/superpathways are Pancreatic secretion and Gastric acid production. The drugs Pharmaceutical Solutions and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, testes and liver, and related phenotypes are digestive/alimentary and growth/size/body region

Wikipedia : 74 Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack of... more...

Related Diseases for Exocrine Pancreatic Insufficiency

Diseases related to Exocrine Pancreatic Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 shwachman-diamond syndrome 1 32.6 SBDS ELANE EFL1
2 pancreatic agenesis 1 32.3 SPINK1 SCT PNLIP PDX1 CFTR
3 diarrhea 30.9 TNF SCT CFTR CCK
4 calvarial hyperostosis 30.7 COX4I2 COX4I1
5 pancreas, annular 30.4 SPINK1 PTF1A
6 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 30.3 PDX1 CEL
7 alcoholic pancreatitis 30.2 SPINK1 SCT CFTR CCK
8 autoimmune pancreatitis 30.1 TNF CTLA4 CFTR
9 pancreatic steatorrhea 29.9 SCT PNLIP CELA3B CELA1 CCK
10 maturity-onset diabetes of the young 29.9 PTF1A PDX1 CELA3B CEL
11 celiac disease 1 29.8 TNF SCT CTLA4 CELA3B CELA1 CCK
12 bronchiectasis 29.8 TNF ELANE CFTR
13 diabetes mellitus 29.6 TNF SPINK1 SCT PTF1A PDX1 CTLA4
14 pancreatic adenocarcinoma 29.6 TNF SPINK1 SCT CFTR CCK
15 acute pancreatitis 29.3 TNF SPINK1 SCT PNLIP ELANE CFTR
16 pancreatitis 28.2 UBR1 TNF SPINK1 SCT PTF1A PNLIP
17 exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis 13.0
18 johanson-blizzard syndrome 11.9
19 cystic fibrosis 11.8
20 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 11.6
21 pancreatic agenesis 2 11.4
22 neutropenia, severe congenital, 8, autosomal dominant 11.4
23 pancreatic cancer 10.5
24 pancreas, dorsal, agenesis of 10.5 PTF1A PDX1
25 overgrowth syndrome 10.5
26 neutropenia 10.4
27 functionless pituitary adenoma 10.4 CCKAR CCK
28 acalculous cholecystitis 10.4 CCKAR CCK
29 microscopic polyangiitis 10.4 TNF CTLA4
30 gastroduodenal crohn's disease 10.4 TNF CCK
31 spotted fever rickettsiosis 10.4 TNF CTLA4
32 skin sarcoidosis 10.3 TNF CTLA4
33 dysostosis 10.3
34 prss1-related hereditary pancreatitis 10.3 SPINK1 CFTR
35 opioid addiction 10.3 CCKAR CCK
36 rickets 10.3
37 alcohol use disorder 10.3
38 irritable bowel syndrome 10.3
39 duodenal ulcer 10.3 TNF SCT CCK
40 nontuberculous mycobacterial lung disease 10.2 TNF CFTR
41 mycobacterium abscessus 10.2 TNF CFTR
42 fibrosis of extraocular muscles, congenital, 1 10.2
43 pyle disease 10.2
44 vitamin b12 deficiency 10.2
45 pancreas disease 10.2
46 lipomatosis 10.2
47 liver cirrhosis 10.2
48 intestinal disease 10.2
49 hypoglycemia 10.2
50 pustular psoriasis 10.2 TNF ELANE

Graphical network of the top 20 diseases related to Exocrine Pancreatic Insufficiency:



Diseases related to Exocrine Pancreatic Insufficiency

Symptoms & Phenotypes for Exocrine Pancreatic Insufficiency

MGI Mouse Phenotypes related to Exocrine Pancreatic Insufficiency:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.11 CCKAR CEL CFTR CTLA4 PDX1 PNLIP
2 growth/size/body region MP:0005378 10.03 CCKAR CEL CFTR COX4I1 COX4I2 PDX1
3 endocrine/exocrine gland MP:0005379 10.02 CCK CCKAR CFTR CTLA4 PDX1 PTF1A
4 homeostasis/metabolism MP:0005376 10 CCK CCKAR CEL CFTR COX4I2 CTLA4
5 liver/biliary system MP:0005370 9.61 CCKAR CEL CFTR CTLA4 PDX1 PNLIP
6 respiratory system MP:0005388 9.17 CCKAR CELA1 CFTR COX4I2 CTLA4 PTF1A

Drugs & Therapeutics for Exocrine Pancreatic Insufficiency

Drugs for Exocrine Pancreatic Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pharmaceutical Solutions Phase 3
2
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
3
Choline Approved, Nutraceutical Phase 2 62-49-7 305
4 Bile Acids and Salts Phase 2
5 Omega 3 Fatty Acid Phase 2
6 Nootropic Agents Phase 2
7 Hypolipidemic Agents Phase 2
8 Flax Phase 2
9 Lecithin Phase 2
10 Lipid Regulating Agents Phase 2
11 Sunflower Phase 2
12 Antimetabolites Phase 2
13 Soy Bean Phase 2
14 Proton Pump Inhibitors Phase 2
15 Anti-Ulcer Agents Phase 2
16 Antacids Phase 2
17
Phylloquinone Approved, Investigational Phase 1 84-80-0
18
Menadione Approved, Nutraceutical Phase 1 58-27-5 4055
19 Menaquinone Investigational Phase 1 1182-68-9
20 Vitamins Phase 1
21 Trace Elements Phase 1
22 Micronutrients Phase 1
23 Nutrients Phase 1
24 Hemostatics Phase 1
25 Vitamin K Phase 1
26 naphthoquinone Phase 1
27 Antifibrinolytic Agents Phase 1
28 Coagulants Phase 1
29
Saxagliptin Approved 361442-04-8 11243969
30
Repaglinide Approved, Investigational 135062-02-1 65981
31
Glucagon Approved 16941-32-5
32
carbamide peroxide Approved 124-43-6
33
gastric inhibitory polypeptide Investigational 100040-31-1
34 HIV Protease Inhibitors
35 Hypoglycemic Agents
36
protease inhibitors
37 Incretins
38 Dipeptidyl-Peptidase IV Inhibitors
39 Sitagliptin Phosphate
40 insulin
41 Insulin, Globin Zinc
42 Glucagon-Like Peptide 1
43 Liver Extracts

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
2 An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT02823964 Phase 4 Liprotamase
3 A Multicenter, Open-Label, Safety Extension of Study PR-011 Titled: A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) Completed NCT01131507 Phase 4 EUR-1008 (APT-1008)
4 An Open-label, Multicenter, Randomized, Cross-over Study to Compare the Safety and Efficacy of PANZYTRAT® 25,000 to KREON® 25,000 in the Control of Steatorrhea in Subjects Aged 7 Years and Older With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) Completed NCT01327703 Phase 4 Panzytrat® 25,000;Kreon® 25,000
5 A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) Completed NCT01100606 Phase 4 EUR-1008 (APT-1008);EUR-1008 (APT-1008)
6 One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year Completed NCT00535756 Phase 4 Creon;Placebo
7 Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
8 MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea Completed NCT00572975 Phase 4
9 A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site, in Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis Recruiting NCT03924947 Phase 4 Pancrelipase
10 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Enrolling by invitation NCT03642093 Phase 4
11 Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects Not yet recruiting NCT03859869 Phase 4 Pancrelipase;Placebo
12 Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency Terminated NCT00744250 Phase 4 Pancrelipase
13 Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
14 A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Withdrawn NCT02009410 Phase 4 Creon;Creon 25000 matching Placebo
15 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
16 Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Unknown status NCT01012908 Phase 2, Phase 3
17 An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449904 Phase 3 Liprotamase
18 A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT02734810 Phase 3 Liprotamase Powder for Oral Solution
19 A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed NCT01641393 Phase 3 EUR-1008 25,000 Units;Kreon 25,000 Units
20 A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449878 Phase 3 Liprotamase;Placebo
21 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Completed NCT00414908 Phase 3 Pancrelipase delayed release capsule;Placebo Comparator
22 An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00981214 Phase 3 EUR-1008 (APT-1008)
23 A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy Completed NCT00400842 Phase 3 SA-001;SA-001;Placebo
24 A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
25 A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF) Completed NCT00408317 Phase 3 Ultrase® MT20;Placebo
26 A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency Completed NCT00559364 Phase 3 Viokase® 16;Placebo;Proton pump inhibitor (PPI);Omeprazole
27 An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00775528 Phase 3 Pancrelipase Delayed Release
28 A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00690820 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
29 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02137382 Phase 3 Creon®;Creon N
30 A Randomized Double-blind (Withdrawal) Phase 3 Study to Evaluate the Efficacy and Tolerability of Pancrelipase MT Capsules Compared With Placebo in the Treatment of Subjects With Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Completed NCT00662675 Phase 3 Pancrease MT 10.5, or MT 21;Placebo for Pancrease MT 10.5 or MT 21
31 A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00297167 Phase 3 EUR-1008 (APT-1008);Placebo;Placebo;EUR-1008 (APT-1008)
32 A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy Completed NCT00401076 Phase 3 SA-001
33 A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension Completed NCT00705978 Phase 3 Pancreatin;Placebo
34 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI) Completed NCT00788593 Phase 3 Placebo;EUR-1008 (APT-1008) High Dose;EUR-1008 (APT-1008) Low Dose
35 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis Completed NCT00432861 Phase 3 PANCRECARB® (pancrelipase);Placebo
36 An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT01747330 Phase 3 Pancreatin
37 Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old Completed NCT00880100 Phase 3 Ultrase® MT12
38 Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Completed NCT00513682 Phase 3 Ultrase® MT20
39 Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects Recruiting NCT03450772 Phase 3 Creon® 25000;Creon® 10000
40 A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Active, not recruiting NCT03051490 Phase 3 Liprotamase;porcine PERT
41 An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy Terminated NCT00500084 Phase 3 Liprotamase
42 A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Completed NCT00095732 Phase 2 Liprotamase;Placebo
43 A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT01710644 Phase 1, Phase 2 Burlulipase;Placebo (Caramel in sterile water)
44 A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy Completed NCT03481803 Phase 2 MS1819-SD
45 An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI). Completed NCT00559052 Phase 2 VIOKASE 16
46 A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02415959 Phase 2 Creon IR;Creon® (DR/GR)
47 An Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic Insufficiency Completed NCT00743483 Phase 2 rhBSSL
48 A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients With Type 2 Diabetes Mellitus, and to Investigate the Pharmacokinetics of EPANOVA® and OMACOR® Following a Single Oral Dose in Patients With Different Degrees of PEI Completed NCT02370537 Phase 2 Epanova® (omega-3 carboxylic acids);Omacor® (omega-3-acid ethyl esters)
49 Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF Completed NCT00406536 Phase 2
50 A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Recruiting NCT03746483 Phase 2 MS1819-SD;Porcine PERT

Search NIH Clinical Center for Exocrine Pancreatic Insufficiency

Cochrane evidence based reviews: exocrine pancreatic insufficiency

Genetic Tests for Exocrine Pancreatic Insufficiency

Anatomical Context for Exocrine Pancreatic Insufficiency

MalaCards organs/tissues related to Exocrine Pancreatic Insufficiency:

40
Testes, Pancreas, Liver, Bone, Lung, Bone Marrow, Small Intestine
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Exocrine Pancreatic Insufficiency:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells Affected by disease, potential therapeutic candidate

Publications for Exocrine Pancreatic Insufficiency

Articles related to Exocrine Pancreatic Insufficiency:

(show top 50) (show all 1145)
# Title Authors PMID Year
1
13C-labeled mixed triglyceride breath test (13C MTG-BT) in healthy children and children with cystic fibrosis (CF) under pancreatic enzyme replacement therapy (PERT): a pilot study. 54 61
18817766 2008
2
Exocrine pancreatic insufficiency in the Eurasian dog breed--inheritance and exclusion of two candidate genes. 54 61
17302791 2007
3
Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? 54 61
17269988 2007
4
Does secretin-stimulated MRCP predict exocrine pancreatic insufficiency?: A comparison with noninvasive exocrine pancreatic function tests. 54 61
17016144 2006
5
Homozygous (TG)11 allele in intron 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has a protective role against bicarbonate decrease in pure pancreatic juice among Japanese male alcoholics. 54 61
15645646 2004
6
[New fecal markers: recent developments and perspectives]. 54 61
15550893 2004
7
Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. 54 61
12604981 2003
8
Faecal elastase 1 concentration is a marker of duodenal enteropathy. 54 61
11806885 2002
9
[Maldigestion during chronic pancreatitis]. 54 61
11458612 2001
10
Comparison of fecal elastase-1 determination with the secretin-cholecystokinin test in patients with cystic fibrosis. 54 61
10192202 1999
11
Comparative clinical evaluation of the 13C-mixed triglyceride breath test as an indirect pancreatic function test. 54 61
9548629 1998
12
13C-starch breath test--comparative clinical evaluation of an indirect pancreatic function test. 54 61
9106982 1997
13
Intraduodenal free fatty acids rather than triglycerides are responsible for the release of CCK in humans. 54 61
8981511 1997
14
Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. 54 61
8595714 1996
15
Maldigestion after total gastrectomy is associated with pancreatic insufficiency. 54 61
8607504 1996
16
[Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function]. 54 61
8761139 1996
17
Lack of accuracy of plasma alpha-amino nitrogen profiles as an indicator of exocrine pancreatic function both after continuous and bolus stimulation of the pancreas with secretin and cholecystokinin-pancreozymin. 54 61
7871858 1994
18
Adenovirus-mediated transfer of human lipase complementary DNA to the gallbladder. 54 61
8194711 1994
19
[The diagnostic value of the amino acid absorption test in detection of a disorder of exocrine pancreatic function]. 54 61
1636270 1992
20
Fecal isoamylase activity in patients with pancreatic diseases. 54 61
1704633 1991
21
Inflammatory bowel disease in Shwachman-Diamond syndrome; is there an association? 61
31196706 2020
22
Broadening the phenotypic spectrum of Pearson syndrome: Five new cases and a review of the literature. 61
31825167 2020
23
Association of multiple patient and disease characteristics with the presence and type of pain in chronic pancreatitis. 61
31314128 2020
24
ACG Clinical Guideline: Chronic Pancreatitis. 61
32022720 2020
25
Characterization of all the lipolytic activities in pancreatin and comparison with porcine and human pancreatic juices. 61
31288050 2020
26
Surgical Management of Solid Pseudopapillary Neoplasms of Pancreas: A Single-Center Experience of 60 Patients. 61
31958791 2020
27
Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer Is Not Severe. 61
30650423 2020
28
Severe forms of Johanson-Blizzard syndrome caused by two novel compound heterozygous variants in UBR1: Clinical manifestations, imaging findings and molecular genetics. 61
31980351 2020
29
Chronic Pancreatitis: Managing a Difficult Disease. 61
31764092 2020
30
Histopathology and Feline Pancreatic Lipase Immunoreactivity in Inflammatory, Hyperplastic and Neoplastic Pancreatic Diseases in Cats. 61
31955805 2020
31
Diagnostic and Therapeutic Management of Post-Gastric Bypass Chronic Diarrhea: a Systematic Review. 61
31902043 2020
32
Exocrine pancreatic and enterocyte function in patients with advanced pancreatic cancer. 61
30579666 2019
33
Growth and Nutrition in Cystic Fibrosis. 61
31659726 2019
34
The baseline nutritional status assessed by MUST score has a low accuracy in predicting the risk of hospitalization during follow-up in patients with chronic pancreatitis: A cohort study. 61
31926768 2019
35
Acute oxalate nephropathy due to high vitamin C doses and exocrine pancreatic insufficiency. 61
31748360 2019
36
In vitro digestion models to assess lipolysis: The impact of the simulated conditions of gastric and intestinal pH, bile salts and digestive fluids. 61
31554063 2019
37
The 2019 ESPEN Arvid Wretlind lecture perioperative nutritional and metabolic care: Patient-tailored or organ-specific approach? 61
31732291 2019
38
Pancreatic Malnutrition in Children. 61
31710363 2019
39
Management of Exocrine Pancreatic Insufficiency in Children. 61
31535732 2019
40
Alcohol-related chronic exocrine pancreatic insufficiency: diagnosis and therapeutic management. A proposal for treatment by the Italian Association for the Study of the Pancreas (AISP) and the Italian Society of Alcohology (SIA). 61
30938130 2019
41
Secondary hyperoxaluria due to pancreatic insufficiency. 61
31814577 2019
42
Comparison of pancreas-sparing duodenectomy (PSD) and pancreatoduodenectomy (PD) for the management of duodenal polyposis syndromes. 61
31474487 2019
43
Recurrent Leg Ulcer, Underweight, Short Stature, and Exocrine Pancreatic Insufficiency. 61
31634262 2019
44
Natural history of SPINK1 germline mutation related-pancreatitis. 61
31628023 2019
45
Role of Fibre in Nutritional Management of Pancreatic Diseases. 61
31540004 2019
46
Chronic Pancreatitis and Bone Disease. 61
31558406 2019
47
Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders. 61
31268981 2019
48
Lower Gastrointestinal Conditions: Malabsorption Syndromes. 61
31411845 2019
49
Prehabilitation in patients undergoing pancreaticoduodenectomy: a randomized controlled trial. 61
31232076 2019
50
Risk Factors for Rapid Progression From Acute Recurrent to Chronic Pancreatitis in Children: Report From INSPPIRE. 61
31136562 2019

Variations for Exocrine Pancreatic Insufficiency

Expression for Exocrine Pancreatic Insufficiency

Search GEO for disease gene expression data for Exocrine Pancreatic Insufficiency.

Pathways for Exocrine Pancreatic Insufficiency

Pathways related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.18 SCT PNLIP CFTR CELA3B CEL CCKAR
2 9.8 SCT CCK

GO Terms for Exocrine Pancreatic Insufficiency

Cellular components related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 TNF SPINK1 SCT PNLIP ELANE CELA3B
2 mitochondrial respiratory chain complex IV GO:0005751 8.96 COX4I2 COX4I1

Biological processes related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 embryonic digestive tract development GO:0048566 9.43 TNF SCT
2 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.4 TNF ELANE
3 intestinal cholesterol absorption GO:0030299 9.37 PNLIP CEL
4 mature ribosome assembly GO:0042256 9.32 SBDS EFL1
5 pancreatic juice secretion GO:0030157 9.26 SCT CEL
6 lipid digestion GO:0044241 9.16 PNLIP CEL
7 generation of precursor metabolites and energy GO:0006091 9.13 PDX1 COX4I2 COX4I1
8 exocrine pancreas development GO:0031017 8.8 PTF1A PDX1 CELA1

Sources for Exocrine Pancreatic Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....